Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES RECEIVING ORAL DECITABINE AND CEDAZURIDINE OR INTRAVENOUS/SUBCUTANEOUS HYPOMETHYLATING AGENTS IN A REAL-WORLD SETTING

Journal article

Peer reviewed

A. Zeidan, A. Martin, H. Costantino, K. Modi, T. Salimi, T. Washington and R. Epstein

Leukemia research, Vol.128, p.107262

05/2023

Metrics

1 Record Views

Title: Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES RECEIVING ORAL DECITABINE AND CEDAZURIDINE OR INTRAVENOUS/SUBCUTANEOUS HYPOMETHYLATING AGENTS IN A REAL-WORLD SETTING
Creators - without role: A. Zeidan - Yale Cancer Center
A. Martin - Cerner (United States)
H. Costantino - Cerner (United States)
K. Modi - Cerner (United States)
T. Salimi - Taiho Oncology (United States)
T. Washington - Taiho Oncology (United States)
R. Epstein - Product Innovation and Engineering (United States) (United States, Saint James) - LLC
Publication Details: Leukemia research, Vol.128, p.107262
Publisher: Elsevier Ltd
Identifiers: 9911729809846
Academic Unit: Science, Mathematics and Technology (SMT)
Language: English
Resource Type: Journal article